CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 482 enrolled
Drug / intervention
Somatropindrug
Likely dose
Somatropin 0.23 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01897766
NCT01897766N/ACompleted

AN INVESTIGATION INTENDED TO EVALUATE THE LONG-TERM EFFICACY AND SAFETY OF GENOTROPIN IN CHILDREN WITH SGA DWARFISM WITHOUT EPIPHYSEAL CLOSURE. (RETROSPECTIVE STUDY)

Pfizer·observational·Posted Jul 12, 2013·Updated Sep 25, 2023

In Brief

An observational study evaluating Somatropin for Small for Gestational Age (SGA). Completed, enrolled 482 participants.

Detailed Summary

The objective of this surveillance is to collect Safety and Effectiveness information for Long term Use of Somatropin for Patients with a Small for Gestational Age (SGA).

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
Countries--
Collaborators--

Timeline

N/ACompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedJul 12, 2013
Enrollment StartSep 5, 2013
Primary CompletionFeb 28, 2017
Study CompletionJun 7, 2017
TodayJul 2, 2026
Enrollment to primary: 3.5 yearsPosted 13.0 years ago

Interventions

Somatropindrug

0.23 mg to 0.48 mg/kg/week